Company Encyclopedia
View More
name
Scinai Immunotherapeutics
SCNI.US
Scinai Immunotherapeutics Ltd., a biopharmaceutical company, focuses on developing, manufacturing, and commercializing inflammation and immunology biological products for the treatment of infectious and autoimmune diseases in Israel. It develops nanosized VHH antibodies (nanoAbs) targeting diseases with unmet medical needs; and PC111, a monoclonal antibody for treating pemphigus, steven johnson’s syndrome, and toxic epidermal necrolysis. The company also provides contract development and manufacturing organization services to biotech companies. It has licensing and collaboration agreement with Max Planck Society and University Medical Center Gottingen for the development and commercialization of COVID-19 nanosized antibody.
1.936 T
SCNI.USMarket value -Rank by Market Cap -/-

Financial Score

27/12/2025 Update
C
BiotechnologyIndustry
Industry Ranking174/400
Industry medianC
Industry averageD
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreD
    • ROE-13.73%E
    • Profit Margin448.39%A
    • Gross Margin-164.29%E
  • Growth ScoreA
    • Revenue YoY303.87%A
    • Net Profit YoY109.37%A
    • Total Assets YoY-20.27%E
    • Net Assets YoY207.88%A
  • Cash ScoreB
    • Cash Flow Margin330.55%C
    • OCF YoY303.87%A
  • Operating ScoreE
    • Turnover0.09E
  • Debt ScoreB
    • Gearing Ratio33.63%B

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    12 Health Care Stocks Moving In Friday's Pre-Market Session

    In Friday's pre-market session, Can Fite Biofarma's stock surged by 41.8%, Scinai Immunotherapeutics rose by 14.66%, and Agape ATP increased by 13.21%. SciSparc, Biodexa Pharmaceuticals, and AlphaTON Capital also saw gains. Conversely, Biohaven's stock fell by 16.2%, Athira Pharma decreased by 9.02%, and Adagio Medical Holdings dropped by 8.5%. China Pharma Holding, Indaptus Therapeutics, and EUDA Health Holdings also experienced declines.

    benzinga_article·
    US
    EUDA
    -11.55%
    US
    SCNI
    -6.20%
    US
    ATHA
    +3.74%
    benzinga_article·
    US
    EUDA
    -11.55%
    US
    SCNI
    -6.20%
    US
    ATHA
    +3.74%

    Scinai Immunotherapeutics Ltd. Held Annual Shareholder Meeting

    Scinai Immunotherapeutics Ltd. held its Annual Meeting of Shareholders on December 22, 2025. Shareholders approved the re-election of Mark Germain to the board, a voluntary agreement for certain board members to step down, a grant of American Depository Shares to Dr. Tamar Ben-Yedidia, and the appointment of Zvi Haft as the company’s auditors for 2025.

    Reuters·
    US
    SCNI
    -6.20%
    Reuters·
    US
    SCNI
    -6.20%

    U.S. stock night trading fluctuations: Scinai Immunotherapeutics surged 20.17% in night trading, with active capital flow attracting market attention

    Scinai Immunotherapeutics rose 20.17% in after-hours trading; BeiGene fell 1.92% in after-hours trading, with a transaction volume of USD 1.2 million; Recursion Pharmaceuticals fell 2.38% in after-hours trading, with a transaction volume of USD 755,000; Radiopharm Theranostics fell 42.24% in after-hours trading, with a transaction volume of USD 616,600

    Tracking Unusual Activity·
    US
    SCNI
    -6.20%
    Tracking Unusual Activity·
    US
    SCNI
    -6.20%

    Scinai Reports Nine-Month 2025 Results as CDMO Growth Continues and NanoAbs Pipeline Advances | SCNI Stock News

    Scinai Immunotherapeutics Ltd. reported a revenue increase to $1,049k for the first nine months of 2025, driven by its expanding CDMO business. R&D expenses decreased, while marketing expenses rose slightly. The company faced a net loss of $6,244k, contrasting with a profit in 2024 due to prior financial income from loan conversion. Scinai's CDMO business is growing, with a new sterile fill-and-finish system planned for 2026. The NanoAbs pipeline is advancing, with grant applications pending. The PC111 program is under strategic review after a grant application was denied.

    StockTitan·
    US
    SCNI
    -6.20%
    StockTitan·
    US
    SCNI
    -6.20%

    Scinai Immunotherapeutics Announces Board Changes and New Accounting Firm Amid Cost-Cutting Efforts

    Scinai Immunotherapeutics announced the resignation of two board members and plans to replace its accounting firm, PwC, with Ziv Haft to reduce costs. These changes are part of the company's financial recovery efforts, facing challenges like negative cash flows and high debt levels. The stock is rated Neutral by TipRanks' AI Analyst, with moderate market confidence and attractive valuation for value investors.

    Tip Ranks·
    US
    SCNI
    -6.20%
    Tip Ranks·
    US
    SCNI
    -6.20%
    © 2025 Longbridge｜Disclaimer